Manufacturing Process Development for Belzutifan, Part 1: A Concise Synthesis of the Indanone Starting Material-Reference-Cited by-同舟云学术

Manufacturing Process Development for Belzutifan, Part 1: A Concise Synthesis of the Indanone Starting Material

Published:2021-11-07 Issue: Volume: Page:
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Peng Feng¹^ORCID,Tan Lushi¹,Chen Lu²,Dalby Stephen M.¹,DiRocco Daniel A.¹,Duan Jianjun²,Feng Minyi²,Gong Guan²,Guo Haiheng²,Hethcox J. Caleb¹,Jin Lu²,Johnson Heather C.¹,Kim Jungchul¹^ORCID,Le Diane¹,Lin Yipeng²,Liu Wenjun¹,Shen Jun²,Wan Yimei²,Xiao Chengqian²,Xiang Bangping¹^ORCID,Xiang Qun²,Xu Jing¹,Yan Luliang²,Yang Weiyi²,Ye Honglin²,Yu Yanpei²,Zhang Jun²

Affiliation:

1. Process Research and Development, Merck & Co. Inc., Rahway, New Jersey 07065, United States

2. Shanghai SynTheAll Pharmaceutical Co. Ltd., 9 Yuegong Road, Jinshan District, Shanghai 201507, China

Funder

Merck

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00236

Reference37 articles.

1. American Cancer Society. Key Statistics about Kidney Cancer. https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html (accessed 2019-04-17).

2. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma

3. Manufacturing Process Development for Belzutifan, Part 2: A Continuous Flow Visible-Light-Induced Benzylic Bromination

4. Manufacturing Process Development for Belzutifan, Part 3: Completing a Streamlined Through-Process with a Safe and Scalable Oxidation

5. Manufacturing Process Development for Belzutifan, Part 4: Nitrogen Flow Criticality for Transfer Hydrogenation Control

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Kilogram Scale Delivery of MK-7845 as a Potential COVID-19 Therapy: Rapid Process Development of Key Intermediates;Organic Process Research & Development;2024-05-16

2. Enantio- and Diastereoselective Total Synthesis of Belzutifan Enabled by Rh-Catalyzed Hydrogenation;Organic Letters;2024-05-06

3. Engineering Hydroxylase Activity, Selectivity, and Stability for a Scalable Concise Synthesis of a Key Intermediate to Belzutifan;Angewandte Chemie International Edition;2024-02-19

4. Engineering Hydroxylase Activity, Selectivity, and Stability for a Scalable Concise Synthesis of a Key Intermediate to Belzutifan;Angewandte Chemie;2024-02-19

5. Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 5─Chemoenzymatic Diastereoselective Fluorination/DKR;Organic Process Research & Development;2024-02-07